{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-001757","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.511806+00:00","generated_at":"2026-06-19T12:45:59.592634+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Palatin reports Q2 FY2023 net loss $1.4M, Vyleesi net revenue up 18% QoQ","bullets":["Net loss of $1.4M ($0.13/share) improved from $8.7M loss ($0.91) YoY; includes $4.7M tax benefit.","Vyleesi net product revenue $1.0M, up 18% vs prior quarter; prescriptions dispensed up 12%.","PL9643 Phase 3 dry eye trial enrollment on track; topline data expected mid-2023.","PL8177 Phase 2 UC trial commenced; interim analysis H1 2023, topline H2 2023.","Cash $21.2M plus $6.5M receivables; sufficient through calendar 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-001757","json":"https://secwatch.observer/filing/0001654954-23-001757.json","markdown":"https://secwatch.observer/filing/0001654954-23-001757.md","text":"https://secwatch.observer/filing/0001654954-23-001757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495423001757/0001654954-23-001757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495423001757/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T12:45:59.592634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7087e162c8794d9360fab3c8c835440d284236dd","claim":"PALATIN TECHNOLOGIES INC reported fiscal second quarter ended December 31, 2022 results: revenue $1 million.","evidence_excerpt":"value metrics, notably net product sales increased 18% and prescriptions dispensed increased 12% over the prior quarter. We are excited that net product revenue of approximately $1 million for the quarter ended December 31, 2022, exceeded Vyleesi operating expenses.” Business Highlights and Recent Updates · Anti-Inflammatory / Autoimmune Programs o PL9643","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/911216/000165495423001757/0001654954-23-001757-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter ended December 31, 2022"},{"label":"Revenue","value":"$1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}